Experts Review Current And Future Research Into New Multiple Myeloma Treatments
Earlier this year, an international group of myeloma experts published a review of ongoing research into new myeloma treatments. This review not only described a wide range of potential new myeloma...
View ArticleASH 2011 Multiple Myeloma Update – Day Three Afternoon: Other New Therapies
As the third day of the 2011 American Society of Hematology (ASH) annual meeting came to an end, attendees could look back on an agenda that featured presentations about a wide range of potential new...
View ArticlePanobinostat Combination May Be Effective In Relapsed And Velcade-Refractory...
Interim results from a Phase 2 study show that panobinostat may be clinically beneficial for certain multiple myeloma patients with advanced disease. In the study, patients who had relapsed and were no...
View ArticleMyeloma Research To Be Presented At The American Society of Clinical...
The 48th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 1, through Tuesday, June 5, in Chicago. More than 25,000 clinical specialists from all over the...
View ArticleASCO 2012 Multiple Myeloma Update – Day Three: New Myeloma Treatments
Today was the third day of the American Society of Clinical Oncology (ASCO) annual meeting, and the morning was filled with oral presentations about important myeloma-related studies. Most of the...
View ArticleASCO 2012 Multiple Myeloma Update – Day Four: Poster Presentations On New...
This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through tomorrow. However, today is the last day with any...
View ArticleBeyond Kyprolis And Pomalyst: What Is Next On The Horizon?
Within the past nine months, two new agents have been approved for the treatment of relapsed multiple myeloma. In July 2012, a second generation proteasome inhibitor, Kyprolis (carfilzomib), was...
View ArticleLatest Myeloma Research To Be Presented At The American Society Of Clinical...
The American Society of Clinical Oncology will hold its 49th annual meeting May 31 through June 4 in Chicago. Similar to previous years, more than 25,000 clinical specialists from all over the world...
View ArticleThe Future Of Treatment For Multiple Myeloma
In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest...
View ArticleASCO 2013 Multiple Myeloma Update – Day Four: Poster Presentations
This year’s American Society of Clinical Oncology (ASCO), which was held in Chicago, began on Friday and concluded on Tuesday. Monday was the busiest day at the meeting with regard to myeloma research....
View ArticlePanobinostat-Velcade-Dexamethasone Combination Continues To Show Promise For...
Final results from a recent Phase 2 clinical trial continue to indicate that panobinostat in combination with Velcade and dexamethasone is effective for heavily pretreated multiple myeloma. In the...
View ArticleASH 2013 Preview: Treatments In Mid- To Late-Stage Clinical Development For...
The Beacon continues today with its ‘ASH preview’ series about myeloma research that will be presented at the American Society of Hematology (ASH) meeting in early December. Abstracts for the...
View Article
